51 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
with motixafortide, the study’s independent DMC issued a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit … factors can delay the commencement and rate of completion of clinical trials, including the inability to recruit patients at the expected rate
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
the need to recruit all 177 patients originally planned for the study. In accordance with the DMC’s recommendation, study enrollment was completed
6-K
EX-99
BLRX
Bioline Rx Ltd
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study
6-K
EX-99
om3xu7
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
424B5
2z08v6i
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
zphnhbk5blhfchbn
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
hg6npetai 7m2x
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
h8lwctu3kn2m8q
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am
6-K
EX-99
qrzojors4l71k6 k0wff
18 Aug 21
BioLineRx Reports Second Quarter 2021 Financial Results
7:01am
6-K
EX-99
sn7nf02 nlm
26 May 21
BioLineRx Reports First Quarter 2021 Financial Results
7:54am
424B5
2wm19 wsarsycl
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
cbcz12 loil57n3czb8
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
80h9gxlk 7a
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
glo29 j5t6
31 Dec 20
Prospectus supplement for primary offering
4:31pm
6-K
EX-99
7zcez pa7nrdh
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
424B5
nkvez 90j3f50vm9e1
13 Nov 20
Prospectus supplement for primary offering
4:31pm